FDA
-
-
-
-
-
-
-
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
-
-
-
-
-
-
-
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
-
-
-
-
-
-
-
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
-
-
-
-
-
-
-
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
-
-
-
-
-
-
-
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
-
-
-
-
-
-
-
Citius Oncology partners with Verix AI for LYMPHIR launch
-
-
-
-
-
-
-
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
-
328,149 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

